We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Section: news

Overcoming Resistance in ALK-Positive NSCLC: The Emergence of APG-2449 as a Novel FAK and Third-Generation TKI

MedXY Editorial Team•Jan 9, 2026•news
targeted therapy

Highlights

Dual-Mechanism Efficacy

APG-2449 acts as both a third-generation ALK/ROS1 tyrosine kinase inhibitor (TKI) and a focal adhesion kinase (FAK) inhibitor, addressing resistance pathways that often bypass traditional TKI therapy.

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Open language-specific specialty feeds and department pages.

Bendamustine as a Novel Single-Agent Therapy in High Burden T-Cell Large Granular Lymphocytic Leukemia: Clinical Efficacy and STAT3 Pathway InhibitionBendamustine monotherapy achieved high response rates and inhibited STAT3 signaling in patients with high burden T-cell large granular lymphocytic leukemia, showing promise as an effective and well-tolerated treatment option.Sep 18, 2026Targeting Acute Myeloid Leukemia through Multi-Functional Small Molecules: Insights from Cheminformatics and Mitochondrial ModulationCheminformatic screening identified novel small molecules with apoptotic, autophagic, and reductase-inhibitory activities that selectively kill AML cells, induce mitochondrial dysfunction, and synergize with current therapies, highlightingSep 1, 2026Ivosidenib Monotherapy Shows Promise in IDH1 Mutated Myelodysplastic Neoplasm/Syndrome: A Phase 2 StudyIvosidenib monotherapy demonstrates substantial efficacy and safety in IDH1 mutated myelodysplastic neoplasm, especially in treatment-naïve high-risk patients, offering a new therapeutic option.Aug 28, 2026
Loading comments...
MedXY briefing

Get the free newsletter

Evidence-led clinical news, trends, and analysis—delivered to your inbox.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
Decoding Neuroendocrine Carcinomas: Proteomic Insights Define Subtypes, Biomarkers, and Therapeutic Opportunities
Comprehensive proteomic and phosphoproteomic profiling of 267 neuroendocrine carcinomas across multiple tissues reveals distinct molecular subtypes, biomarkers, and a novel NAD+ metabolic vulnerability, advancing personalized precision medi
Aug 28, 2026
Erythrocytosis in Advanced Thyroid Cancer Therapy: Emerging Safety Concerns with Targeted AgentsErythrocytosis is an underreported hematologic side effect of targeted therapies in advanced thyroid cancers, notably RET inhibitors, occurring early and recurrently without impacting survival outcomes but correlating with disease control rJun 28, 2026
A Novel Approach to Targeting DLL3 with Tarlatamab in a Patient with Medullary Thyroid Carcinoma after Progression on SelpercatinibThis case report details successful management of RET-altered medullary thyroid carcinoma using tarlatamab after selpercatinib progression, highlighting modified dosing to mitigate toxicities and achieve complete response.Jun 11, 2026